Document is current
Any future updates will be listed below
-
Authors
Villanueva-Millan, Maria Jesus
Leite, Gabriela
Mathur, Ruchi
Rezaie, Ali
Fajardo, Cristina Moreno
de Freitas Germano, Juliana
Morales, Walter
Sanchez, Maritza
Rivera, Ignacio
Parodi, Gonzalo
Weitsman, Stacy
Rashid, Mohamad
Hosseini, Ava
Brimberry, Daniel
Barlow, Gillian M.
Pimentel, Mark https://orcid.org/0000-0002-0619-5115
-
Funding
Funding for this research was provided by:
Scott Gray Foundation
Arrillaga Foundation
Justine Stamen Arrillaga & John Arrillaga
the Steve Perry Foundation
the Eli Gottesdiener Foundation
the Nima Taghavi Foundation
the DiCecco Family Foundation
National Philanthropic Trust
Cedars-Sinai Medical Center
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 28 May 2025
First Online: 26 June 2025
Declarations
:
: Competing Interests: M.P. is a consultant for Ferring Pharmaceuticals Inc., Salvo Health, Dieta Health, Cylinder Health Inc., and Vivante Health Inc. M.P. has received grant support from Bausch Health and Synthetic Biologics. R.M. has received grant support from Bausch Health. A.R. is a consultant/speaker for and has received grant support from Bausch Health. Cedars-Sinai has a licensing agreement with Gemelli Biotech and Hobbs Medical. A.R., M.P., and R.M. have equity in Gemelli Biotech and GoodLFE. M. P. has equity in Cylinder Health and Salvo Health. The remaining authors report no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The REIMAGINE study protocol was approved by the Cedars-Sinai Institutional Review Board (Pro00035192), and all participants provided informed written consent prior to participation.
